Gland Pharma Share Price Jumps 16.22% to Rs 2,170, Hits 52-Week High on Q4 FY26 Results: PAT Nearly Doubles, CDMO Grows 65%

The Gland Pharma share price surged 16.22 percent to Rs 2,170 on 18 May 2026, hitting a fresh 52-week high, as the company reported exceptional Q4 FY26 results. Net profit for the quarter ended 31 March 2026 jumped 96.56 percent year-on-year to Rs 366.67 crore, revenue grew 22.30 percent to Rs 1,742.79 crore and EBITDA surged 48 percent to Rs 513 crore with margins expanding to 29.4 percent. The company also declared a final dividend of Rs 20 per share, providing an income catalyst alongside the strong growth numbers.

The Gland Pharma share price hitting a 52-week high of Rs 2,170 on a day when the broader market was under pressure from crude above $111 and the rupee at a record low of 96.17 demonstrates the exceptional relative strength of the pharma sector in the current crisis. This is a rare case of a stock outperforming massively on a macro-challenged market day, driven purely by business fundamentals.

Gland Pharma Q4 FY26 Results: Key Numbers Behind the Share Price Surge

• Q4 FY26 Net Profit: Rs 366.67 crore (up 96.56% YoY from Rs 186.54 crore in Q4 FY25)
• Q4 FY26 Revenue from Operations: Rs 1,742.79 crore (up 22.30% YoY from Rs 1,424.90 crore)
• Q4 FY26 EBITDA: Rs 513 crore (up 48% YoY)
• Q4 FY26 EBITDA Margin: 29.4% (significant expansion from prior year)
• CDMO Segment Contribution: 25% of total revenues, growing 65% YoY — the primary growth engine
• Base Business Adjusted EBITDA Margin: 38% (exceptional for a generic injectable manufacturer)
• Final Dividend: Rs 20 per equity share
• 52-Week High Hit on 18 May: Rs 2,170 (Gland Pharma share price intraday peak during 16.22% surge)
• 52-Week Low: Rs 1,452.20 (19 May 2025)
• 52-Week High (new): Rs 2,170 (18 May 2026)
• Market Cap at 52-Week High: Over Rs 35,000 crore
• 3-Year Return: 133% as of 18 May 2026
• 1-Year Return: Approximately 50%

Track Gland Pharma share price live, Q4 results details and broker targets on the Check the Univest Screener for live data.

What Drove Gland Pharma Share Price to 52-Week High

CDMO Segment Growth of 65%: The Key Differentiator

The Contract Development and Manufacturing Organisation (CDMO) segment is the primary driver behind the Gland Pharma share price surge. CDMO revenue grew 65 percent year-on-year to contribute 25 percent of total Q4 FY26 revenues. CDMO is a high-margin, high-value business where global pharmaceutical companies outsource complex manufacturing to trusted partners like Gland Pharma. As global pharma companies restructure supply chains away from Chinese manufacturers post-COVID, Indian CDMO players like Gland Pharma are winning long-term contracts that provide multi-year revenue visibility.

The 65 percent CDMO growth on top of already elevated revenue is exceptional and directly explains why the Gland Pharma share price reacted with a 16 percent single-day jump. CDMO contracts are typically multi-year, high-margin and sticky, suggesting the earnings quality of this Q4 result is superior to a typical product sales beat.

38% Adjusted Base Business EBITDA Margin: Quality Earnings

Beyond the CDMO segment, Gland Pharma’s base injectable generics business achieved an adjusted EBITDA margin of 38 percent. This is one of the highest margins in India’s generic pharmaceutical space and reflects the premium pricing power of complex injectable formulations, the company’s operational efficiency and the favourable product mix shift toward higher-value molecules. The Gland Pharma share price responding to this with a 16 percent gain reflects justified re-rating of earnings quality.

Rs 20 Dividend: Income Plus Growth Signal

The Rs 20 per share final dividend declaration reinforces management’s confidence in cash flow generation and future earnings trajectory. For a stock trading at Rs 2,170, the Rs 20 dividend represents a 0.92 percent yield for the quarter alone. The dividend signal is additionally important because it confirms that the strong Q4 earnings are genuine cash-backed profits, not accounting adjustments.

Tap to Access Best Research Pieces on Univest

Should You Buy Gland Pharma at Rs 2,170?

The Bull Case for Buying

The Gland Pharma share price at Rs 2,170 still carries multi-year upside if the CDMO growth trajectory continues. BusinessToday notes the stock has gained 133 percent in three years and approximately 50 percent in the last year, both suggesting sustained institutional accumulation rather than a speculative spike. The CDMO opportunity driven by global pharma supply chain restructuring is a 5 to 10 year theme, not a one-quarter event. Analyst targets from before today’s result ranged from Rs 1,964 (average of 12 analysts at Investing.com) to Rs 2,500 (high estimate), suggesting the Rs 2,170 Gland Pharma share price may still have room to run toward the higher targets as upgrades follow the results.

The pharma sector’s resilience on a day when the broad market is under pressure from crude and rupee headwinds makes Gland Pharma and its peers particularly attractive for investors seeking uncorrelated wealth creation. Pharma as a sector is completely unaffected by the crude oil crisis, as VK Vijayakumar of Geojit noted.

The Caution Case: Stretched Valuation After 16% Move

The Gland Pharma share price at Rs 2,170 trades at an elevated premium to its book value and reflects significant growth expectations already being priced in after the 16 percent single-day move. Investors who missed the move should not chase the Gland Pharma share price in the immediate session. Wait for either a post-result consolidation dip toward Rs 2,000 to Rs 2,050 or a broader market pullback that creates a secondary entry point.

Key risk for the Gland Pharma share price: US market concentration. Revenue from the US stood at approximately Rs 744 crore (Q1 FY26 data), making US regulatory risk and pricing pressure a real factor. Any USFDA import alert, warning letter or pricing disruption in the US market could compress the CDMO growth narrative quickly.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces on Gland Pharma share price live alerts, Q4 result analysis and pharma sector research!

Gland Pharma vs Nifty Pharma: Sector Leadership Confirmed

The Nifty Pharma index hit a 52-week high in May 2026 and Gland Pharma’s 16 percent surge confirms the sector’s leadership position in the current market environment. Other pharma names showing strength include Torrent Pharma (at its all-time high of Rs 4,516), Astrazeneca Pharma (recovering from lows), Cipla (bouncing 3.7% despite weak Q4 results on impairment-only basis) and Sun Pharma (benefiting from rupee weakness and export growth). The pharma sector is the single clearest portfolio safe harbour during the 2026 crude oil shock market environment.

Conclusion

The Gland Pharma share price surge of 16.22 percent to a 52-week high of Rs 2,170 on 18 May 2026 is one of the most significant single-day moves in the pharma sector in 2026, driven by a near-doubling of Q4 FY26 net profit, 65 percent CDMO growth, 29.4 percent EBITDA margins and a Rs 20 per share final dividend. The result confirms Gland Pharma’s positioning as India’s leading generic injectable CDMO player in the global supply chain restructuring opportunity. Investors who missed the move should wait for a post-results consolidation dip rather than chasing at 52-week highs. Consult a SEBI-registered advisor before making any buy or hold decision on the Gland Pharma share price.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

FAQs

Why did the Gland Pharma share price jump 16% today?

Ans. The Gland Pharma share price surged 16.22 percent because Q4 FY26 net profit nearly doubled, rising 96.56 percent year-on-year to Rs 366.67 crore. Revenue grew 22.30 percent to Rs 1,742.79 crore, EBITDA rose 48 percent to Rs 513 crore with 29.4 percent margin, and the CDMO segment grew 65 percent to contribute 25 percent of revenues. The board also declared a Rs 20 per share final dividend.

What is the Gland Pharma share price 52-week high?

Ans. The Gland Pharma share price hit a new 52-week high of Rs 2,170 on 18 May 2026 during its 16.22 percent single-day rally. The previous 52-week low was Rs 1,452.20 on 19 May 2025, meaning the stock has appreciated approximately 49.4 percent from its 52-week trough to the new 52-week high.

Should you buy Gland Pharma at the current share price?

Ans. The Gland Pharma share price at Rs 2,170 reflects strong Q4 FY26 fundamentals and a 65 percent CDMO growth engine. The CDMO theme (global pharma supply chain restructuring) is a multi-year opportunity. However, after a 16 percent single-day move, the stock is momentum-extended. Patient investors may wait for post-result consolidation toward Rs 2,000 to Rs 2,050 before entering. Consult a SEBI-registered advisor before acting on the Gland Pharma share price.

What is the CDMO segment and why did it grow 65%?

Ans. CDMO (Contract Development and Manufacturing Organisation) is a high-margin business where global pharmaceutical companies outsource complex drug manufacturing to specialist partners. Gland Pharma’s CDMO segment grew 65 percent year-on-year in Q4 FY26 because global pharma companies are restructuring supply chains away from Chinese manufacturers. India’s CDMO players, led by Gland Pharma, are winning long-term multi-year contracts as a result. This structural trend supports multi-year growth for the Gland Pharma share price.